Eli Lilly announced over 150 partnering / licensing deals since 2005, with over 14 deals in 2012 alone.
Analysis of the partnering deals shows a strong emphasis on partnerships in metabolic, oncology, psychiatry, central nervous system and cardiovascular diseases.
Abstracted from: Partnering Deals and Alliances with Eli Lilly
The number of partnering, collaborative R&D and licensing deals announced varied year on year with a slight decline recently from the peak of 34 deals announced in 2008. This was probably due to the effects of the 2008 economic crisis making companies more selective in their deal making as budgets were squeezed.
The following figure shows the level of Eli Lilly deal announcements since 2005.
Figure 1: Eli Lilly partnering deals 2005-2012
Source: Current Agreements, 2013
Analysis of the partnering deals shows a strong emphasis on partnerships in metabolic, oncology, psychiatry, central nervous system and cardiovascular diseases. This reflects the focus areas of Eli Lilly strongly.
The following table provides an overview of the partnering deals announced by Eli Lilly based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Deals and Alliances with Eli Lilly
Figure 2: Eli Lilly partnering deals by therapy area 2005-2013
Source: Current Agreements, 2013
Further analysis of these deals shows that Eli Lilly has a preference for collaborative R&D, development and licensing deals, similar to many other top pharmaceutical or big pharma companies. Such deals provide the right for Eli Lilly to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.
The following table provides an overview of the deals announced by Eli Lilly based on deal type disclosed.
Figure 3: Eli Lilly partnering deals by deal type 2005-2013
Source: Current Agreements, 2013
When looking at stage of development at deal signing, the most popular stage at signing is discovery with 35 deal announcements, followed closely by preclinical stage with 31 deal announcements.
Eli Lilly is also active in partnering at phase I, phase II and phase III stage deals. Such deals are of on-going importance to all top pharmaceutical companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.
The following table provides an overview of the deals announced by Eli Lilly based on stage of development at signature.
Figure 4: Eli Lilly partnering by stage of development 2005-2013
Source: Current Agreements, 2013
Eli Lilly has signed over 150 partnering, collaborative R&D and licensing deals since 2005. The following provides a summary of the top deals by headline value.
Figure 5: Top Eli Lilly partnering deals by headline value 2005-2013
Source: Current Agreements, 2013
Our report provides more detailed insight into the details of each deal. See: Partnering Deals and Alliances with Eli Lilly
Eli Lilly partnering at Current Agreements
View all deals for Eli Lilly: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Deals and Alliances with Eli Lilly
More
Summary profile data for Eli Lilly
Partnering interests for Eli Lilly
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Eli Lilly
Report: Partnering Deals and Alliances with Big Pharma
Available resources for deal coverage for Eli Lilly
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Eli Lilly company profile, recent deals, M&A and financing news and articles
Related
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, dealtalk
